Divine Aleru, Microbiome Signatures Research Coordinator

This study shows mercury(II) can bind histidines to inhibit chymotrypsin and trigger irreversible denaturation and aggregation. Imidazole blocks aggregation, aggregation rises above pH 6.5, and histidine-targeting DEPC shifts mercury effects, supporting a two-histidine mechanism.

This review explains how mercury, cadmium, arsenic, and lead disrupt glutathione and cysteine-based defenses. It emphasizes catalytic mercury-driven glutathione oxidation and metal-conjugate breakdown that generates electrophiles and metal sulfides, linking these mechanisms to kidney, neurologic, and carcinogenic injury patterns.

This study shows that mussel metallothionein binds mercury in two main forms: a dominant linear Hg–thiolate complex and a substantial clustered Hg–thiolate structure with Hg–Hg pairing. The clustered form likely concentrates in the α-domain and supports cellular mercury detoxification.

What was studied? This original research study used large-scale bioinformatics to map where mercury detoxification genes occur across prokaryotes and to infer how those genes evolved. The authors screened 84,032 bacterial and archaeal genomes, including isolate genomes, metagenome-assembled genomes, and single-cell genomes, for mercuric reductase (MerA), which reduces Hg(II) to volatile Hg(0), and organomercury lyase […]

What was reviewed? This review explained how mercury cycles through air, water, and soil and how microbes control key steps that change mercury toxicity. It focused on mercury-resistant bacteria and the mer operon as a practical framework for understanding detoxification and resistance. The authors also compared physical and chemical cleanup approaches with biologic approaches, arguing […]

This review explains how mercury-tolerant bacteria, fungi, and microalgae resist and transform mercury. It highlights detox genes such as the mer system, biofilm binding, and redox-driven methylation and demethylation that change mercury toxicity and exposure risk across ecosystems.

This review explains that mercury toxicity largely comes from binding thiol groups in cysteine, glutathione, and proteins. That binding disrupts enzymes, antioxidant defenses, and signaling, driving oxidative stress, mitochondrial injury, and multi-organ effects that may also influence gut barrier stress and downstream microbiome function.

This study shows that methylmercury delivered as a cysteine complex increases liver and mitochondrial mercury uptake and worsens mitochondrial stress. Methionine pre-treatment lowers mercury uptake, preserves oxygen use, and protects mitochondrial function and cell viability in rat liver slices.

This study shows that mercury cysteine conjugates act like amino acids and directly affect sulfur metabolism enzymes. Human GTK can use and inhibit these conjugates, while cystathionine γ-lyase is irreversibly inactivated at low micromolar mercury levels, expanding how mercury can drive toxicity.

This review explains how inorganic mercury and methylmercury enter the gut, kidney, liver, brain, and placenta by binding to thiols and mimicking nutrients that use amino acid and organic anion transporters, which helps predict where mercury accumulates and how chelators enhance excretion.

This study shows that low, environmentally relevant mercury levels can boost plasmid transfer of antibiotic resistance genes between E. coli by driving oxidative stress, membrane damage, and transfer-gene activation, while very high mercury levels suppress transfer by harming cells.

This study measured mercury in urine and hair in dental workers and controls and linked urine mercury to the number of amalgam fillings. Levels stayed below occupational limits, but fillings still acted as a steady exposure source.

This review explains how inorganic and methylmercury disrupt gut microbes, metabolites, tight junctions, and immune signals, making the gut a key target tissue that can drive liver and brain toxicity through gut–liver and gut–brain pathways.

This review explains how heavy metals and microplastics work together to drive antimicrobial resistance by enriching biofilms, speeding gene transfer, and co-selecting metal and antibiotic resistance in soil and water microbiomes, creating environmental reservoirs that can feed resistant pathogens into humans.

Ferroptosis links metabolism to disease because it depends on iron handling and membrane lipid chemistry. Tumors, neurodegeneration, and organ injury models often shift ferroptosis sensitivity by changing cystine uptake, glutathione levels, GPX4 activity, and alternative antioxidant pathways such as FSP1–CoQ10.

This review explains how gut microbes influence ferroptosis in colorectal cancer through vitamins, bile acids, SCFAs, and tryptophan metabolites. It highlights microbe-linked metabolites that either sensitize tumors to ferroptosis or block it, shaping therapy response and resistance.

This review explains how gut microbiota metabolites—SCFAs, bile acids, and tryptophan products—shape ferroptosis in intestinal epithelial cells and influence IBD severity, highlighting microbial patterns linked to lower butyrate producers and altered bile acid signaling.

This study shows that gut microbiota–derived short-chain fatty acids can reduce erastin-induced lipid peroxidation and modulate iron and ATF3 signaling in cardiomyocytes. The findings link microbial metabolites to ferroptosis control during ischemic-like stress in heart cells.

This review connects gut microbiota dysbiosis to ferroptosis biology in chronic kidney disease, emphasizing how microbial metabolites and altered antioxidant defenses can amplify iron-driven lipid peroxidation. It highlights functional shifts toward fewer SCFA producers and more uremic toxin producers and discusses diet and microbial interventions.

This review explains how ferroptosis drives tubular injury in acute kidney injury through iron overload and lipid peroxidation. It connects key regulators like system Xc−, GPX4, Nrf2, and ACSL4 to AKI models and highlights drug strategies that block ferroptosis.

This review explains how ferroptosis drives lipid peroxidation and brain injury in ischemic and hemorrhagic stroke. It summarizes drug targets and inhibitors such as ferrostatin-1, liproxstatin-1, selenium/GPX4 support, N-acetylcysteine, and iron chelation, and it discusses translation limits.

This study shows that GPX4 protects neurons by anchoring to membranes through a hydrophobic fin-loop. A patient R152H mutation collapses this loop, triggers ferroptosis in patient neurons and organoids, and drives Alzheimer’s-like brain signatures in mice.

This review connects Alzheimer’s neurodegeneration to ferroptosis, an iron-driven, lipid-peroxidation cell-death program. It summarizes human and model evidence linking brain iron, GPX4 antioxidant defense failure, and amyloid/tau-related iron handling to cognitive decline, and outlines therapy angles that target iron–redox stress.

This review links ferroptosis to Alzheimer’s and Parkinson’s disease by connecting iron imbalance, mitochondrial stress, and lipid peroxidation to neuronal loss. It highlights LOX-driven oxidized phospholipids, ACSL4-dependent lipid vulnerability, VDAC2-related iron handling, and ferritinophagy as key mechanisms, and it prioritizes Nrf2/Bach1 as actionable therapeutic targets.